source
- Alkermes reports early proof-of-concept for orexin-2 drug in ADHDAlkermes announced early-stage trial results for ALKS 7290, an orexin‑2 receptor agonist originally being developed for narcolepsy, showing proof of concept in ADHD. The study reported dose‑depend…
- Novartis licenses preclinical radioligand from China's BoomRay in up to $900 million dealNovartis has expanded its radiopharmaceutical pipeline by signing a licensing agreement with Chinese biotech BoomRay Therapeutics. The deal could be worth up to $900 million, including an upfront…